These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 18519793

  • 1. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2008 Jun 01; 14(11):3589-97. PubMed ID: 18519793
    [Abstract] [Full Text] [Related]

  • 2. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R.
    Cancer Res; 2004 Sep 15; 64(18):6626-34. PubMed ID: 15374977
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
    Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M, Osamura RY.
    Pathol Int; 2009 Jan 15; 59(1):19-27. PubMed ID: 19121088
    [Abstract] [Full Text] [Related]

  • 4. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
    Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, Adjei AA.
    Clin Cancer Res; 2007 Feb 15; 13(4):1140-8. PubMed ID: 17317822
    [Abstract] [Full Text] [Related]

  • 5. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY.
    Clin Cancer Res; 2008 Aug 15; 14(16):5124-30. PubMed ID: 18698030
    [Abstract] [Full Text] [Related]

  • 6. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2006 Jan 15; 12(2):634-42. PubMed ID: 16428510
    [Abstract] [Full Text] [Related]

  • 7. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C.
    IUBMB Life; 2007 Nov 15; 59(11):717-21. PubMed ID: 17968710
    [Abstract] [Full Text] [Related]

  • 8. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 9. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
    García-Maceira P, Mateo J.
    Oncogene; 2009 Jan 22; 28(3):313-24. PubMed ID: 18978810
    [Abstract] [Full Text] [Related]

  • 10. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation.
    Jin X, Jin HR, Lee D, Lee JH, Kim SK, Lee JJ.
    Eur J Pharmacol; 2008 Sep 11; 592(1-3):41-7. PubMed ID: 18639543
    [Abstract] [Full Text] [Related]

  • 11. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
    Frost P, Shi Y, Hoang B, Lichtenstein A.
    Oncogene; 2007 Apr 05; 26(16):2255-62. PubMed ID: 17016437
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells.
    Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC.
    Mol Carcinog; 2008 Sep 05; 47(9):686-700. PubMed ID: 18240292
    [Abstract] [Full Text] [Related]

  • 13. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 14. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.
    Anticancer Res; 2008 Mar 01; 28(6A):3801-8. PubMed ID: 19189667
    [Abstract] [Full Text] [Related]

  • 15. Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
    Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, Lu B.
    Oncogene; 2005 Aug 18; 24(35):5414-22. PubMed ID: 15940265
    [Abstract] [Full Text] [Related]

  • 16. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
    Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F.
    Endocr Relat Cancer; 2008 Mar 18; 15(1):257-66. PubMed ID: 18310292
    [Abstract] [Full Text] [Related]

  • 17. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
    Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M.
    Cancer Res; 2006 Jun 01; 66(11):5549-54. PubMed ID: 16740688
    [Abstract] [Full Text] [Related]

  • 18. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.
    Clin Cancer Res; 2008 Nov 15; 14(22):7272-83. PubMed ID: 19010843
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma.
    Yang QC, Zeng BF, Shi ZM, Dong Y, Jiang ZM, Huang J, Lv YM, Yang CX, Liu YW.
    J Exp Clin Cancer Res; 2006 Dec 15; 25(4):593-9. PubMed ID: 17310851
    [Abstract] [Full Text] [Related]

  • 20. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
    Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, Debus JU, Weber KJ, Huber PE.
    Int J Radiat Oncol Biol Phys; 2004 Nov 15; 60(4):1220-32. PubMed ID: 15519795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.